ES2184084T3 - Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual. - Google Patents

Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual.

Info

Publication number
ES2184084T3
ES2184084T3 ES97919596T ES97919596T ES2184084T3 ES 2184084 T3 ES2184084 T3 ES 2184084T3 ES 97919596 T ES97919596 T ES 97919596T ES 97919596 T ES97919596 T ES 97919596T ES 2184084 T3 ES2184084 T3 ES 2184084T3
Authority
ES
Spain
Prior art keywords
manufacture
interferons
stabilization
pads
sublingual administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97919596T
Other languages
English (en)
Inventor
Peter R Rothschild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERONPATENT Ltd
Original Assignee
FERONPATENT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERONPATENT Ltd filed Critical FERONPATENT Ltd
Application granted granted Critical
Publication of ES2184084T3 publication Critical patent/ES2184084T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LOS INTERFERONES NATURAL Y RECOMBINANTE SE ESTABILIZAN CON AGUA BIDESTILADA, LACTOSA, ALBUMINA, MONO - Y DIHIDROFOSFATOS SODICOS, (C 5 H 10 O 5 ) N , COMO LA GOMA ARABIGA, Y SUELTOS Y DILUIDOS EN SOLUCION DE ETANOL AL 20% HASTA EL CUARTO LUGAR DECIMAL, POR PROCEDIMIENTO HOMEOPATICO. LA SOLUCION FINAL SE PULVERIZA SOBRE UN EXCIPIENTE QUE COMPRENDE UN 20% DE GOMA ARABIGA, UN 30% DE LACTOSA Y UN 50% DE ALMIDON PARA FABRICAR TABLETAS DE 100 MG, CADA UNA DE LAS CUALES CONTIENE 200 U.I. DE ALFA - INTERFERON HUMANO. LAS TABLETAS SE ADMINISTRAN SUBLINGUALMENTE AL PACIENTE PARA TRATAMIENTO DE INFECCIONES VIRALES SENSIBLES AL INTERFERON.
ES97919596T 1996-05-09 1997-05-09 Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual. Expired - Lifetime ES2184084T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9600433 1996-05-09

Publications (1)

Publication Number Publication Date
ES2184084T3 true ES2184084T3 (es) 2003-04-01

Family

ID=11004429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97919596T Expired - Lifetime ES2184084T3 (es) 1996-05-09 1997-05-09 Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual.

Country Status (8)

Country Link
EP (1) EP0920329B1 (es)
AP (1) AP1168A (es)
AT (1) ATE224725T1 (es)
AU (1) AU2401197A (es)
DE (1) DE69715883T2 (es)
DK (1) DK0920329T3 (es)
ES (1) ES2184084T3 (es)
WO (1) WO1997041885A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041885A1 (en) * 1996-05-09 1997-11-13 Feronpatent Limited Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets
JP2001526662A (ja) * 1997-05-09 2001-12-18 フェロンパテント リミテッド 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
WO1999006429A1 (fr) * 1997-08-01 1999-02-11 Toray Industries, Inc. Stabilisation de proteines utiles et compositions a base de proteines utiles
FR2836379B1 (fr) * 2002-02-28 2007-06-01 Dit Bon Michel Betend Formes galeniques solides de medicaments homeopathiques, dont les allergenes ou antigenes, en dilutions homeopathiques pour preparation extemporanee pour un seul individu pour administration sublinguale
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
EP1749018B1 (en) * 2004-04-23 2014-10-22 Expedeon Limited Methods and kits for stabilising, protecting and solubilising proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH156609A (de) * 1931-01-27 1932-08-15 Chem Pharm Lab Bika V Poehlman Verfahren zur Herstellung eines trockenen, homöopathischen Heilmittels.
EP0123291A2 (en) * 1983-04-20 1984-10-31 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing interferon
DE3484374D1 (de) * 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
FR2619714B1 (fr) * 1987-09-02 1991-07-12 Medibrevex Nouvelles formes galeniques de theophylline pour administration par voie per- et sublinguale
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
WO1997041885A1 (en) * 1996-05-09 1997-11-13 Feronpatent Limited Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets

Also Published As

Publication number Publication date
ATE224725T1 (de) 2002-10-15
EP0920329B1 (en) 2002-09-25
EP0920329A1 (en) 1999-06-09
DK0920329T3 (da) 2003-01-27
DE69715883D1 (de) 2002-10-31
AP1168A (en) 2003-06-30
DE69715883T2 (de) 2003-07-31
AU2401197A (en) 1997-11-26
AP9901682A0 (en) 1999-12-31
WO1997041885A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
ES2069582T3 (es) Nucleosidos terapeuticos.
MY107843A (en) Anti-viral compounds.
NO875209L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidinnukleosider.
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
NO870441L (no) Farmasoeytiske preparatformer for stabilisering av alfa-interferon.
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
ATE63747T1 (de) Antivirale verbindungen.
ES2184084T3 (es) Estabilizacion de interferones en disolucion acuosa para la fabricacion de pastillas de administracion sublingual.
AR038455A1 (es) Brivudina estabilizada en formulaciones topicas
NO970847D0 (no) 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
ES2052922T3 (es) Nucleosidos terapeuticos.
IT8722031A0 (it) Formulazioni farmaceutiche e forme di dosaggio per la somministrazione rettale di calcitonina.
TR199900523T2 (xx) Vir�s k�kenli hastal�klar�n tedavisi i�in farmas�tik bile�imler.
AU3354997A (en) Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases
ATE371737T1 (de) Proteaseresistente flint-analoge
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
MX9303985A (es) Nucleosidos terapeuticos.
EE9900346A (et) Viljatusevastane ja viljastumisvõimet tõstev ravim